Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.73 |
| ▸ | PDGFRA | P16234 | 12/20 | 0.73 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.73 |
| ▸ | FLT3 | P36888 | 3/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.73 |
| ▸ | KIT | P10721 | 2/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.73 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30891518 | 1.00 | CSF1R (0.73) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL31740343 | 0.90 | CSF1R (0.57) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL31741155 | 0.89 | CSF1R (0.78) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16046106 | 0.84 | CSF1R (0.73) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| Vimseltinib SCHEMBL30453793 | 0.84 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| Vimseltinib SCHEMBL16047448 | 0.84 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL31740888 | 0.84 | CSF1R (0.51) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL16046817 | 0.84 | CSF1R (0.80) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| Vimseltinib SCHEMBL31615255 | 0.84 | CSF1R (0.98) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 | |
| SCHEMBL30562950 | 0.83 | CSF1R (0.51) | CSF1RPDGFRAPDGFRBFLT3CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617775-B2 | Processes of making CSF-1R inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-05-05 | — | — | US | disclosed |
| US-12582655-B2 | Methods of treating disorders using CSFIR inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260034131-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2026-02-05 | — | — | US | disclosed |
| US-12509443-B2 | CSF-1R inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250368621-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250368622-A1 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12485120-B2 | Methods of treating disorders using CSF1R inhibitors | DECIPHERA PHARMACEUTICALS, LLC (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4647767-A2 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | Deciphera Pharmaceuticals, LLC (US) | 2025-11-12 | — | — | EP | disclosed |
| EP-4303583-B1 | CSF1R INHIBITORS FOR USE IN TREATING TENOSYNOVIAL GIANT CELL TUMORS | DECIPHERA PHARMACEUTICALS LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250205237-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2025-06-26 | — | — | US | disclosed |
| EP-2968286-B1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2968286-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9181223-B2 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181223-B2 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181223-B2 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-10 | — | — | US | disclosed |
| WO-2014145025-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014145025-A2 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034131-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | CSF1R, CSF3R, ARG1 | CSF1R 1/4885PDGFRA 289/4885PDGFRB 132/4885 |
| US-12509443-B2 | CSF-1R inhibitors and methods of use thereof | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRA 133/4885PDGFRB 91/4885 |
| US-12617775-B2 | Processes of making CSF-1R inhibitors and methods of use thereof | CSF1R, CSF3R, FLT3 | CSF1R 1/4885PDGFRA 41/4885PDGFRB 27/4885 |
| US-20250368621-A1 | CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF1R, CSF3R, CMKLR1 | CSF1R 1/4885PDGFRA 136/4885PDGFRB 81/4885 |
| US-12485120-B2 | Methods of treating disorders using CSF1R inhibitors | CSF1R, CSF3R, CD68 | CSF1R 1/4885PDGFRA 299/4885PDGFRB 168/4885 |
| US-20250205237-A1 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | CSF1R, CSF3R, CD68 | CSF1R 1/4885PDGFRA 299/4885PDGFRB 168/4885 |
| US-12582655-B2 | Methods of treating disorders using CSFIR inhibitors | CSF1R, CSF3R, MSR1 | CSF1R 1/4885PDGFRA 242/4885PDGFRB 92/4885 |
| US-20250368622-A1 | PROCESSES OF MAKING CSF-1R INHIBITORS AND METHODS OF USE THEREOF | CSF3R, CSF1R, FLT3 | CSF1R 2/4885PDGFRA 149/4885PDGFRB 29/4885 |
| US-20140275085-A1 | 2-AMINOPYRIMIDIN-6-ONES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | CSF1R, KIT, CSF3R | CSF1R 1/4885PDGFRA 6/4885PDGFRB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.